Compare Delta Air Lines, Inc. (DAL) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Delta Air Lines, Inc. vs Merck & Co., Inc. — how do they compare? Delta Air Lines, Inc. trades at $82.4 (market cap $54.56B), while Merck & Co., Inc. trades at $142.38 (market cap $352.29B). The key difference: Merck & Co., Inc. is far larger — about 6.5× Delta Air Lines, Inc.'s market cap, and Merck & Co., Inc. pays the higher dividend (2.38%). Which is the better fit depends on your goals — on Pluang, investors hold Delta Air Lines, Inc. for 97 Days and Merck & Co., Inc. for 98 Days on average.
| DAL | MRK | |
|---|---|---|
Market Cap | $54.56B | $352.29B |
Volume | 6,532,736 | 6,348,796 |
Sector | Industrials | Health |
52-Week High | $93.66 | $156.43 |
52-Week Low | $55.65 | $82.49 |
Typical Hold Time | 97 Days | 98 Days |
Enterprise Value | $69.88B | $399.05B |
Dividend Yield | 1.04% | 2.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Delta Air Lines (DAL) trades at $82.14, down 1.82% on the day, with a bearish technical signal despite strong fundamentals. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. DAL maintains solid profitability with 5.78% net margin and 20.12% ROE, while trading at attractive valuations with P/E of 13.76 and P/S of 0.8. Recent news highlights competitive pressures from United and American's customer poaching efforts and Delta's decision to use Amazon's internet service over Starlink.
DAL presents a compelling value opportunity with strong analyst support (82% buy ratings) and 26% upside to consensus target of $103.36. However, near-term risks include fuel cost volatility, competitive threats to premium customers, and execution challenges. The improving cash flow trend with $1.08B net cash generation in 2025 supports dividend sustainability and operational flexibility.
Merck (MRK) trades at $142.40, up 0.33% on the day, with a bearish technical signal but strong analyst support. The company reported revenue of $65.0B in 2025 with a net income margin of 28.07%, though 2026 projections show a sharp decline to 4.76%. Recent acquisition activity includes the tender offer for Terns Pharmaceuticals to bolster its oncology pipeline, while cash flow trends indicate significant investing outflows in 2026.
The outlook is mixed: robust fundamentals and a consensus price target of $159.59 suggest upside, but high valuation ratios (P/E 114.23) and projected earnings volatility pose risks. Investors should weigh strong institutional buying against technical weakness and competitive pressures in the pharma sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Delta Air Lines, Inc.
Atlanta-based Delta Air Lines is one of the world's largest airlines, with a network of over 300 destinations in more than 50 countries. Delta operates a hub-and-spoke system network, where it gathers and distributes passengers across the globe through key locations such as Atlanta, New York, Salt Lake City, Detroit, Seattle, and Minneapolis-St. Paul. Delta's sale of frequent flier miles, particularly to American Express, is a major driver of the firm's profits.
Read more on DAL →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
